Compare PMTS & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | STIM |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.4M | 140.6M |
| IPO Year | 2015 | 2018 |
| Metric | PMTS | STIM |
|---|---|---|
| Price | $16.08 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $27.67 | $3.00 |
| AVG Volume (30 Days) | 39.2K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $312,189,000.00 | $52,776,000.00 |
| Revenue This Year | $9.95 | $11.10 |
| Revenue Next Year | $10.02 | $11.92 |
| P/E Ratio | $92.29 | ★ N/A |
| Revenue Growth | ★ 12.27 | N/A |
| 52 Week Low | $10.81 | $0.80 |
| 52 Week High | $25.37 | $4.84 |
| Indicator | PMTS | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 38.06 |
| Support Level | $13.87 | $0.80 |
| Resistance Level | $16.38 | $1.55 |
| Average True Range (ATR) | 1.16 | 0.20 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 31.92 | 4.78 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.